| 20.83 0.17 (0.82%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.71 | 1-year : | 28.25 |
| Resists | First : | 22.02 | Second : | 24.19 |
| Pivot price | 20.01  |
|||
| Supports | First : | 18.51 | Second : | 15.4 |
| MAs | MA(5) : | 21.34  |
MA(20) : | 20.61 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 51 |
D(3) : | 56.3 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 28.22 | Low : | 18.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KLRA ] has closed below upper band by 40.0%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 21.12 - 21.25 | 21.25 - 21.34 |
| Low: | 19.32 - 19.47 | 19.47 - 19.58 |
| Close: | 20.25 - 20.48 | 20.48 - 20.65 |
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
Fri, 26 Jun 2026
Enterprise value to revenue forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Fri, 26 Jun 2026
Kailera Therapeutics, Inc. (KLRA) Return On Assets (TTM) - Zacks Investment Research
Thu, 25 Jun 2026
Kailera Therapeutics, Inc. (KLRA) Price Book Value - Zacks Investment Research
Wed, 24 Jun 2026
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Sun, 21 Jun 2026
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P TMI Index - marketscreener.com
Fri, 17 Apr 2026
Kailera Therapeutics announces $625 million IPO - The Pharma Letter
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 8660 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1,950 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.8 % |
| Return on Equity (ttm) | -37 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -11.5 |
| PEG Ratio | 0 |
| Price to Book value | -1.14 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.69e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|